Fig. 1.

Efficacy results of the mixed treatment comparison of infliximab-biosimilar versus other biologicals in RA–ACR20 and ACR50 response at week 24. The infliximab-biosimilar study presented results for week 30. The figure presents odds ratios (OR) between treatments. If the point estimate is greater than 1, then the biosimilar treatment is more effective (although not necessarily statistically significantly more effective) compared to the originator biologicals. Credibility intervals provide information on whether the difference between treatments is statistically significant. If the CI contains the value 1, the difference is not statistically significant